Dark

Check out our Level2View

CRXT
CLARUS THERAPUTCS HLDGS
stock OTC

Inactive

Sep 6, 2022

0.0475USD-31.159%(-0.0215)2,737,134

Pre-market

0.00USD-100.000%(-0.07)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 19, 2022

06:17AM EST Clarus Therapeutics Expects To Initiate In H2 2022, Phase 2 Trial To Provide Once Daily Oral Testosterone Undecanoate To Treat Male Hypogonadism Benzinga

06:17AM EST Clarus Therapeutics Expects To Initiate In H2 Of 2022 A Phase 2 Clinical Trial To Provide Treatment Of Inflammatory Breast Disease, Expects To Initiate In H2 Of 2022, A Phase 4 Clinical Trial To Provide T Therapy For Female-To-Male Transgender Individuals Benzinga

Jan 18, 2022

09:05AM EST Dr. Jumadilova most recently led clinical development programs at Insmed and Pfizer and has nearly 30 years of combined pharmaceutical and biotech experience GlobeNewswire Inc

Dec 7, 2021

04:05PM EST Proceeds to support the ongoing commercialization of JATENZO (testosterone undecanoate) GlobeNewswire Inc

Dec 3, 2021

09:05AM EST Clarus Therapeutics Announces $15M Private Placement Benzinga

09:05AM EST Proceeds to support the ongoing commercialization of JATENZO (testosterone undecanoate) GlobeNewswire Inc

Nov 30, 2021

04:49PM EST Clarus Therapeutics Announces Issuance Of 2 New Patents For JATENZO Benzinga

09:55AM EST Shares of Clarus Therapeutics Holdings, Inc. (CRXT) jumped over 25% on Tuesday morning after the pharmaceutical company announced that the US Patent and Trademark Office issued two new patents for claims that cover Clarus' oral testosterone replacement product, Jatenzo. RTTNews

09:05AM EST JATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical conditions GlobeNewswire Inc

Nov 23, 2021

10:44AM EST Clarus Therapeutics Granted U.S. Patent Titled 'Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same' Benzinga

Nov 18, 2021

04:12PM EST Clarus Therapeutics Hldgs Q3 Sales $4.30M Up From $2.22M YoY Benzinga

04:05PM EST Third quarter 2021 revenue increased 93% year-over-year to $4.3 million GlobeNewswire Inc

Nov 17, 2021

04:05PM EST Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced it will release its third quarter 2021 financial and operating results on Thursday, November 18, 2021, after the market closes. GlobeNewswire Inc

Oct 26, 2021

09:22AM EDT Clarus Therapeutics Announces Two Notices Of Allowance For Patent Claims Covering JATENZO (testosterone undecanoate) Benzinga

09:05AM EDT JATENZO (testosterone undecanoate) is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical conditions GlobeNewswire Inc

Oct 14, 2021

09:12AM EDT Clarus Therapeutics To Present New Real-World Experience Data For JATENZ At 22nd Annual Fall Scientific Meeting Of SMSNA Benzinga

09:05AM EDT JATENZO (testosterone undecanoate) is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical conditions GlobeNewswire Inc

Oct 13, 2021

03:11PM EDT Mid-Afternoon Market Update: Nasdaq Jumps 100 Points; Jasper Therapeutics Shares Spike Higher Benzinga

01:39PM EDT Mid-Day Market Update: Gold Surges 2%; Neuronetics Shares Plunge Benzinga

01:38PM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2021 Benzinga

01:38PM EDT Truist Securities Initiates Coverage On Clarus Therapeutics Hldgs with Buy Rating, Announces Price Target of $10 Benzinga

10:55AM EDT Clarus Therapeutics Holdings, Inc. (CRXT) shares are surging more than 47 percent on Wednesday morning trade in search of a new resistance. There were no corporate announcements on the day. RTTNews

Oct 6, 2021

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2021 Benzinga

06:01AM EDT Needham Initiates Coverage On Clarus Therapeutics Hldgs with Buy Rating, Announces Price Target of $12 Benzinga

Oct 5, 2021

08:01AM EDT The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout Benzinga

Oct 1, 2021

07:56AM EDT The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO Benzinga

Sep 30, 2021

04:12PM EDT Clarus Therapeutics Files For Offer, Sale Of Up To 19.82M Shares Of Common Stock By Selling Stockholders Benzinga

07:43AM EDT The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug Benzinga

Sep 29, 2021

10:12AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2021 Benzinga

09:22AM EDT Maxim Group Initiates Coverage On Clarus Therapeutics Hldgs with Buy Rating, Announces Price Target of $13 Benzinga

Sep 28, 2021

08:18AM EDT The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive Benzinga

08:16AM EDT The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK To Develop Long-Acting HIV Treatments Benzinga

Sep 22, 2021

09:05AM EDT Clarus Therapeutics Holdings, Inc. (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it will present at the 2021 Cantor Virtual Global Healthcare Conference, Monday, September 27, 2021, 10:40 a.m. ET. GlobeNewswire Inc

Sep 21, 2021

04:33PM EDT 13D Shows H.I.G.-GPII, Inc. Discloses 26.2% Active Stake In Clarus Therapeutics Benzinga

Sep 20, 2021

10:04AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 20, 2021 Benzinga

08:19AM EDT Oppenheimer Initiates Coverage On Clarus Therapeutics Hldgs with Outperform Rating, Announces Price Target of $12 Benzinga

07:18AM EDT Cantor Fitzgerald Initiates Coverage On Clarus Therapeutics Hldgs with Overweight Rating, Announces Price Target of $20 Benzinga

Sep 16, 2021

09:09AM EDT Clarus and McGill University Announce Exclusive Worldwide Licensing Agreement To Develop And Commercialize Technology To Treat Rare Conditions Associated With Coenzyme-Q10 Deficiencies; Clarus To Pay $350K Upfront And Up To $10.5M In Milestones Benzinga

09:05AM EDT Agreement to accelerate development of potential treatments for rare, endocrine, metabolic, and neurological conditions associated with primary and secondary ubiquinone deficiencies which belong to the wider class of mitochondrial diseases GlobeNewswire Inc

Sep 15, 2021

09:05AM EDT Clarus Therapeutics Holdings, Inc. (Nasdaq:CRXT), a specialty pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, Monday, September 20, 2021, 2:05 p.m. ET. GlobeNewswire Inc

Share